

RNAi - Technologies, Markets and Companies

Description: RNA interference (RNAi) or gene silencing involves the use of double stranded RNA (dsRNA). Once inside the cell, this material is processed into short 21-23 nucleotide RNAs termed siRNAs that are used in a sequence-specific manner to recognize and destroy complementary RNA. The report compares RNAi with other antisense approaches using oligonucleotides, aptamers, ribozymes, peptide nucleic acid and locked nucleic acid.

Various RNAi technologies are described, along with design and methods of manufacture of siRNA reagents. These include chemical synthesis by in vitro transcription and use of plasmid or viral vectors. Other approaches to RNAi include DNA-directed RNAi (ddRNAi) that is used to produce dsRNA inside the cell, which is cleaved into siRNA by the action of Dicer, a specific type of RNase III. MicroRNAs are derived by processing of short hairpins that can inhibit the mRNAs. Expressed interfering RNA (eiRNA) is used to express dsRNA intracellularly from DNA plasmids.

Delivery of therapeutics to the target tissues is an important consideration. siRNAs can be delivered to cells in culture by electroporation or by transfection using plasmid or viral vectors. In vivo delivery of siRNAs can be carried out by injection into tissues or blood vessels or use of synthetic and viral vectors.

Because of its ability to silence any gene once the sequence is known, RNAi has been adopted as the research tool to discriminate gene function. After the genome of an organism is sequenced, RNAi can be designed to target every gene in the genome and target for specific phenotypes. Several methods of gene expression analysis are available and there is still need for sensitive methods of detection of gene expression as a baseline and measurement after gene silencing. RNAi microarray has been devised and can be tailored to meet the needs for high throughput screens for identifying appropriate RNAi probes. RNAi is an important method for analyzing gene function and identifying new drug targets that uses double-stranded RNA to knock down or silence specific genes. With the advent of vector-mediated siRNA delivery methods it is now possible to make transgenic animals that can silence gene expression stably. These technologies point to the usefulness of RNAi for drug discovery.

RNAi can be rationally designed to block the expression of any target gene, including genes for which traditional small molecule inhibitors cannot be found. Areas of therapeutic applications include virus infections, cancer, genetic disorders and neurological diseases. Research at academic centers that is relevant to RNAi-based therapeutics is mentioned.

Regulatory, safety and patent issues are discussed. Side effects can result from unintended interaction between an siRNA compound and an unrelated host gene. If RNAi compounds are designed poorly, there is an increased chance for non-specific interaction with host genes that may cause adverse effects in the host. However, there are no major safety concerns and regulations are in preliminary stages as the clinical trials are still ongoing and there are no marketed products. Many of the patents are still pending.

The markets for RNAi are difficult to define as no RNAi-based product is approved yet but several are in clinical trials. The major use of RNAi reagents is in research but it partially overlaps that of drug discovery and therapeutic development. Various markets relevant to RNAi are analyzed from 2012 to 2022. Markets are also analyzed according to technologies and use of siRNAs, miRNAs, etc.

Profiles of 161 companies involved in developing RNAi technologies are presented along with 229 collaborations. They are a mix of companies that supply reagents and technologies (nearly half of all) and companies that use the technologies for drug discovery. Out of these, 33 are developing RNAi-based therapeutics and 34 are involved in microRNAs. The bibliography contains selected 600 publications that are cited in the report. The text is supplemented with 34 tables and 11 figures.

Contents: Executive Summary

1. Technologies for suppressing gene function

- Introduction
- DNA transcription
- RNA
- Non-coding RNA
- RNA research and potential applications
- Role of RNA in regulation of the dihydrofolate reductase gene
- Gene regulation
- Post-transcriptional regulation of gene expression
- Alternative RNA splicing
- Technologies for gene suppression
- Antisense oligonucleotides
- Phosphorodiamidate morpholino oligomers
- Transcription factor decoys
- Aptamers
- Ribozymes
- Aptazymes
- RNA aptamers vs allosteric ribozymes
- RNA Lasso
- Peptide nucleic acid
- PNA-DNA chimeras
- Locked nucleic acid
- Gene silencing
- Post-transcriptional gene silencing
- TargetTron? technology for gene knockout
- Definitions and terminology of RNAi
- RNAi mechanisms
- Non-promoter-associated small RNAs
- Piwi-interacting RNAs in germ cell development
- Relation of RNAi to junk DNA
- RNA editing and RNAi
- Historical landmarks in the development of RNAi

2. RNAi Technologies

- Introduction
- Comparison of antisense and RNAi
- Advantages of antisense over siRNAs
- Advantages of siRNAs over antisense
- RNA aptamers vs siRNA
- RNA Lassos versus siRNA
- Concluding remarks on antisense vs RNAi
- PMOs vs antisense and siRNAs
- ssRNAi
- Antisense vs DNP-ssRNA and DNP-siRNA
- LNA and RNAi
- LNA for gene suppression
- Comparison of LNA and RNAi
- Use of siLNA to improve siRNA
- RNAi versus small molecules
- RNAi in vivo
- Cre-regulated RNAi in vivo
- RNAi kits
- ShortCut™ RNAi Kit
- HiScribe™ RNAi Transcription Kit
- pSUPER RNAi system
- Si2 Silencing Duplex
- Techniques for measuring RNAi-induced gene silencing
- Application of PCR in RNAi
- Real-time quantitative PCR
- Assessment of the silencing effect of siRNA by RT-PCR
- Fluorescence resonance energy transfer probe for RNA interactions
- Bioinformatics tools for design of siRNAs
- Random siRNA design

- Rational siRNA design
- The concept of pooling siRNAs
- Criteria for rational siRNA design
- BLOCK-iT RNAi Designer
- QIAGEN's 2-for-Silencing siRNA Duplexes
- Designing vector-based siRNA
- iRNAChek for designing siRNA
- TROD: T7 RNAi Oligo Designer
- siDirect: siRNA design software
- Prediction of efficacy of siRNAs
- Algorithms for prediction of siRNA efficacy
- siRNA databases
- Production of siRNAs
- Chemical synthesis of short oligonucleotides
- In vitro transcription
- Generation of siRNAs in vivo
- UsiRNAs
- siRNA:DNA hybrid molecules
- Chemical modifications of siRNAs
- Sugar modifications of siRNA
- Phosphate linkage modifications of siRNA
- Modifications to the siRNA overhangs
- Modifications to the duplex architecture
- Applications of chemical modification of siRNAs
- Synthetic RNAs vs siRNAs
- Specificity of siRNAs
- Asymmetric interfering RNA
- Genome-wide data sets for the production of esiRNAs
- ddRNAi for inducing RNAi
- ddRNAi technology
- Advantages of ddRNAi over siRNA
- Short hairpin RNAs
- siRNA versus shRNA
- Circular interfering RNA
- Expressed interfering RNA
- RNA-induced transcriptional silencing complex
- Inhibition of gene expression by antigene RNA
- RNAi vs mRNA modulation by small molecular weight compounds

3. MicroRNA

- Introduction
- miRNA and RISC
- Role of the microprocessor complex in miRNA
- miRNAs compared to siRNAs
- miRNA and stem cells
- Influence of miRNA on stem cell formation and maintenance
- Role of miRNAs in gene regulation during stem cell differentiation
- miRNA databases
- Sanger miRBase miRNA sequence database
- Mapping miRNA genes
- A database of ultraconserved sequences and miRNA function
- A database for miRNA deregulation in human disease
- An database of miRNA-target interactions
- Role of miRNA in gene regulation
- Control of gene expression by miRNA
- miRNA-mediated translational repression involving Piwi
- Transcriptional regulators of ESCs control of miRNA gene expression
- Mechanism of miRNAs-induced silencing of gene expression
- miRNA diagnostics
- Biochemical approach to identification of miRNA
- Computational approaches for the identification of miRNAs
- LNA probes for exploring miRNA

miR-TRAP to identify miRNA targets in vivo
Microarrays for analysis of miRNA gene expression
Microarrays vs quantitative PCR for measuring miRNAs
miRNAs as biomarkers of hepatotoxicity
Modification of in situ hybridization for detection of miRNAs
Nuclease Protection Assay to measure miRNA expression
Real-time PCR for expression profiling of miRNAs
Targeting of miRNAs with antisense oligonucleotides
Silencing miRNAs by antagomirs
New tools for miRNA silencing
Use of HAPIScreen for identification of aptamers against pre-miRNAs
miRNA-regulated lentiviral vectors
miRNAs as drug targets
miRNAs as targets for antisense drugs
Challenges facing use of miRNAs as drug targets
Target specificity of miRNAs
Prediction of miRNA targets
Role of miRNA in human health and disease
Role of miRNAs in regulation of hematopoiesis
Role of miRNA depletion in tissue regeneration
Role of miRNA in regulation of aging
Role of miRNA in inflammation
Role of miRNAs in regulation of immune system
Role of miRNA in the cardiovascular system
Role of miRNAs in development of the cardiovascular system
Role of miRNAs in angiogenesis
Role of miRNA in atherosclerosis
Role of miRNAs in cardiac hypertrophy and failure
Role of miRNAs in conduction and rhythm disorders of the heart
Diagnostic and prognostic value of miRNAs in acute coronary syndrome
miRNA-based approaches for reduction of hypercholesterolemia
miRNA-based approach for restenosis following angioplasty
miRNA gene therapy for ischemic heart disease
miRNAs as therapeutic targets for cardiovascular diseases
Concluding remarks and future prospects of miRNA in the cardiovascular system
Role of miRNAs in the nervous system
miRNAs and addiction
miRNAs in neurodegenerative disorders
miRNAs as biomarkers of Alzheimer's disease
miRNAs in Huntington's disease
miRNA malfunction in spinal motor neuron disease
miRNAs and retinal neurodegenerative disorders
miRNA and stroke
miRNA and schizophrenia
Role of miRNA in viral infections
Role of miRNA in HSV-1 latency
miRNA and autoimmune disorders
miRNA in rheumatoid arthritis
miRNA in systemic lupus erythematosus
miRNAs in gastrointestinal disorders
miRNA-based therapies for the irritable bowel syndrome
miRNA and skin disorders
Role of miRNA in inflammatory skin disorders
Role of miRNAs in cancer
miRNAs linked to the initiation and progression of cancer
Oncomirs
Linking miRNA sequences to cancer using RNA samples
Role of miRNAs in viral oncogenesis
miRNA genes in cancer
miRNAs interaction with p53
miRNAs, embryonic stem cells and cancer
miRNAs and cancer metastases
Role of miRNAs in cancer diagnosis

- Cancer miRNA signature
- miRNA biomarkers in cancer
- Diagnostic value of miRNA in cancer
- Prognostic value of miRNA in cancer
- miRNAs as basis of cancer therapeutics
- Antisense oligonucleotides targeted to miRNA
- Delivery of miRNA mimetics in cancer
- Role of miRNAs in adoptive immunotherapy of cancer
- Restoration of tumor suppressor miRNA may inhibit cancer
- Role of miRNAs in various cancers
- miRNA and glioblastoma multiforme
- miRNA and breast cancer
- miRNA and colorectal cancer
- miRNA and gastrointestinal cancer
- miRNA and leukemia
- miRNA and lymphomas
- miRNA and hepatocellular carcinoma
- miRNA and lung cancer
- miRNA and nasopharyngeal carcinoma
- miRNA and ovarian cancer
- miRNA and pancreatic cancer
- miRNA and prostatic cancer
- miRNA and thyroid cancer
- Future prospects of miRNA therapeutics
- Companies involved in miRNA

4. Methods of delivery in RNAi

- Introduction
- Methods of delivery of oligonucleotides
- Oral and rectal administration
- Pulmonary administration
- Targeted delivery to the CNS
- High flow microinfusion into the brain parenchyma
- Intracellular guidance by special techniques
- Biochemical microinjection
- Liposomes-mediated oligonucleotide delivery
- Polyethylenimine-mediated oligonucleotide delivery
- Delivery of TF Decoys
- Biodegradable microparticles
- Microparticles
- Nanoparticles
- Self-delivering rxRNA
- siRNA delivery technologies
- Local delivery of siRNA
- In vivo delivery of siRNAs by synthetic vectors
- Intracellular delivery of siRNAs
- Delivery of siRNAs with aptamer-siRNA chimeras
- MPG-based delivery of siRNA
- Nanoparticles for intracellular delivery of siRNA
- Protamine-antibody fusion proteins for delivery of siRNA to cells
- Protein transduction domains
- Phosphorothioate stimulated cellular delivery of siRNA
- Targeted delivery of siRNAs by lipid-based technologies
- Delivery of siRNA-lipoplexes
- Lipidoids for delivery of siRNAs
- Neolipid™ technology
- siFECTamine?
- Systemic in vivo delivery of lipophilic siRNAs
- Systemic delivery of siRNAi by lipid nanoparticles
- Challenges and future prospects of lipid-based siRNA delivery
- Electroporation
- Nucleofactor technology

- Visualization of electrotransfer of siRNA at single cell level
- Intravascular delivery of siRNA
- 27mer siRNA duplexes for improved delivery and potency
- TransIT-TKO?
- DNA-based plasmids for delivery of siRNA
- Convergent transcription
- PCR cassettes expressing siRNAs
- Genetically engineered bacteria for delivery of shRNA
- Viral vectors for delivery of siRNA
- Adenoviral vectors
- Adeno-associated virus vectors for shRNA expression
- Baculovirus vector
- Lentiviral vectors
- Retroviral delivery of siRNA
- Transkingdom RNAi delivery by genetically engineered bacteria
- Delivery of siRNA without a vector
- Cell-penetrating peptides for delivery of siRNAs
- Role of nanobiotechnology in siRNA delivery
- Chitosan-coated nanoparticles for siRNA delivery
- Cyclodextrin nanoparticles
- Delivery of gold nanorod-siRNA nanoplex to dopaminergic neurons
- Lipidic aminoglycoside as siRNA nanocarrier
- Lipid nanoparticles-mediated siRNA delivery
- Nanosize liposomes for delivery of siRNA
- PAMAM dendrimers for siRNA delivery
- Polyethylenimine nanoparticles for siRNA delivery
- Polycation-based nanoparticles for siRNA delivery
- Quantum dots to monitor siRNA delivery
- Topical delivery of siRNA- nanoparticle conjugates
- Targeted delivery of siRNAs to specific organs
- siRNA delivery to the CNS
- siRNA delivery to the liver
- siRNA delivery to the lungs
- Control of RNAi and siRNA levels
- siRNA pharmacokinetics in mammalian cells
- Mathematical modeling for determining the dosing schedule of siRNA
- Assessing siRNA pharmacodynamics in animal models
- Research on siRNA delivery funded by the NIH
- Companies involved in delivery technologies for siRNA

5. RNAi in Research

- Introduction
- Basic RNAi research
- Antiviral role of RNAi in animal cells
- Combination of siRNA with green fluorescent protein
- Detection of cancer mutations
- Genes and lifespan
- Inducible and reversible RNAi
- Loss-of-function genetic screens
- Nanoparticles mimic RNAi
- Profiling small RNAs
- RNAi for research in neuroscience
- RNAi and environmental research
- Silencing snoRNA genes
- Study of signaling pathways
- Transgenic RNAi
- Use of RNAi to study insulin action
- Applied RNAi research
- RNAi for gene expression studies
- Microarrays for measuring gene expression in RNAi
- RNAi for functional genomic analysis
- RNAi studies on *C. elegans*

- RNAi studies on Drosophila
- RNAi in planaria
- Testing the specificity of RNAi
- Tissue-specific RNAi
- siRNA-mediated gene silencing
- RNAi libraries
- Universal plasmid siRNA library
- pDual library using plasmid vector
- pHippy plasmid vector library
- siRNA library including miRNAs
- siRNA libraries using pRetroSuper vector
- siRNA produced by enzymatic engineering of DNA
- shRNA libraries
- Enzymatic production of RNAi library
- RNAi and alternative splicing
- RNAi in animal development
- RNAi for creating transgenic animals
- RNAi for creating models of neurological disorders
- Research support for RNAi in US
- RNAi for toxicogenomics
- Role of RNAi in the US biodefense research
- The RNAi Consortium
- Research support for RNAi in Europe
- European Union for RNA Interference Technology
- Research support of RNAi
- Role of RNAi in MitoCheck project
- RNAi Global Initiative
- SIROCCO project

6. RNAi in drug discovery

- Basis of RNAi for drug discovery
- RIP-Chip for study of RNA-protein interactions
- RNAi for identification of genes as therapeutic targets
- Role of siRNAs in drug target identification
- Use of a genome-wide, siRNA library for drug discovery
- Use of arrayed adenoviral siRNA libraries for drug discovery
- RNAi as a tool for assay development
- Targeting human kinases with an siRNA library
- Challenges of drug discovery with RNAi
- Express Track
- SM siRNA Drug Discovery Program
- Genome-wide siRNA screens in mammalian cells
- PhenomicID™
- Natural antisense and ncRNA as drug targets
- RNAi for target validation
- Delivering siRNA for target validation in vivo
- Off-target effects of siRNA-mediated gene silencing
- Bioinformatic approach to off-target effects
- Validation of oncology targets discovered through RNAi screens
- Selection of siRNA versus shRNA for target validation
- Application of RNAi to the druggable genome
- Application of siRNA during preclinical drug development
- siRNAs vs small molecules as drugs
- siRNAs vs antisense drugs
- Chemical modifications for improving siRNA drugs
- RNAi technology in plants for drug discovery and development
- Application of RNAi to poppy plant as source of new drugs

7. Therapeutic applications of RNAi

- Introduction
- Potential of RNAi-based therapies

In vitro applications of siRNA
In vivo applications of RNAi
RNAi and cell therapy
Gene inactivation to study hESCs
RNAi and stem cells
Cell therapy for immune disorders
RNAi gene therapy
Drug-inducible systems for control of gene expression
Potential side effects of RNAi gene therapy
Systemic delivery of siRNAs
In vivo RNAi therapeutic efficacy in animal models of human diseases
Virus infections
RNAi approaches to viral infections
Delivery of siRNAs in viral infections
RNAi applications in HIV
A multiple shRNA approach for silencing of HIV-1
Anti-HIV shRNA for AIDS lymphoma
Aptamer-mediated delivery of anti-HIV siRNAs
Bispecific siRNA constructs
Role of the nef gene during HIV-1 infection and RNAi
siRNA-directed inhibition of HIV-1 infection
Synergistic effect of snRNA and siRNA
Targeting CXCR4 with siRNAs
Targeting CCR5 with siRNAs
Concluding remarks on RNAi approach to HIV/AIDS
Influenza
Inhibition of influenza virus by siRNAs
Delivery of siRNA in influenza
Challenges and future prospects of siRNAs for influenza
Respiratory syncytial and parainfluenza viruses
Coronavirus/severe acute respiratory syndrome
Herpes simplex virus 2
Hepatitis B
Hepatitis C virus
Cytomegalovirus
Ebola virus
siRNA vs antisense oligonucleotides for viral infections
siRNA against methicillin-resistant *S. aureus*
RNAi-based rational approach to antimalarial drug discovery
Inhibiting the growth of malarial parasite by heme-binding DNA aptamers
siRNA-based antimalarial therapeutics
RNAi applications in oncology
Allele-specific inhibition
Drug delivery issues in managing cancer by RNAi approach
Inhibition of oncogenes
Modification of alternative splicing in cancer
Onconase
Overcoming drug resistance in cancer
Targeting fusion proteins in cancer
Increasing chemosensitivity by RNAi
RNAi approach to study TRAIL
RNAi-based logic circuit for identification of specific cancer cells
shRNA-based autologous cancer vaccine
siRNAs for anticancer drug discovery
siRNAs for inducing cancer immunity
siRNAs for inhibition of angiogenesis
siRNA targeting the R2 subunit of ribonucleotide reductase
siRNA for cancer chemoprevention
siHybrids vs siRNAs as anticancer agents
Nanobiotechnology-based delivery of siRNAs
Lipid nanoparticle-based delivery of anticancer siRNAs
Minicells for targeted delivery of nanoscale anticancer therapeutics
Nanoimmunoliposome-based system for targeted delivery of siRNA

Polymer nanoparticles for targeted delivery of anticancer siRNA
RNA nanotechnology for delivery of cancer therapeutics
Targeted delivery of a nanoparticle-siRNA complex in cancer patients
RNAi-based treatment of various cancer types
RNAi-based therapy of brain cancer
RNAi in breast cancer
RNAi for enhancing hyperthermia/chemotherapy in cervical cancer
RNAi and colorectal cancer
RNAi and Ewing's sarcoma
RNAi and leukemias
RNAi and lung cancer
RNAi and melanoma
RNAi and pancreatic cancer
RNAi and prostate cancer
Genetic disorders
RNAi for skin disorders
Experimental studies for RNAi applications in skin disorders
Clinical applications of RNAi in skin disorders
Pachyonychia congenita
Skin scarring
Neurological disorders
RNAi for neurodegenerative disorders
Alzheimer's disease
Parkinson's disease
Amyotrophic lateral sclerosis
Prion diseases
Polyglutamine-induced neurodegeneration
Fragile X syndrome and RNAi
RNAi-based therapy for Huntington's disease
Combination of RNAi and gene therapy to prevent neurodegenerative disease
Role of RNAi in pain therapy
Role of RNAi in repair of spinal cord injury
Role of RNAi in treatment of multiple sclerosis
siRNA for Duchenne muscular dystrophy
siRNA for dystonia
RNAi in ophthalmology
Age related macular degeneration
Current treatment of AMD
RNAi-based treatments for AMD
Diabetic retinopathy
Retinitis pigmentosa
RNAi and metabolic disorders
RNAi and obesity
Genes and regulation of body fat
RNAi and diabetes
Regulation of insulin secretion by a miRNA
RNAi for study of genes in animal models of diabetes
RNAi for drug discovery in diabetes
RNAi for treating liver dysfunction in diabetes
siRNAs for study of glucose transporter
siRNAs for targeting adipose inflammation in diabetes and obesity
RNAi in hematology
Stem cell-based gene therapy and RNAi for sickle cell disease
RNAi and disorders of the immune system
siRNA applications in immunology
Use of RNAi in transplantation
RNAi for cardiovascular disorders
RNAi for hypercholesterolemia
siRNA targeting NADPH oxidase in cardiovascular diseases
siRNA for study and treatment of ischemia-reperfusion injury
RNAi in respiratory disorders
siRNA for cystic fibrosis
siRNA for asthma

- RNAi for musculoskeletal disorders
- RNAi for rheumatoid arthritis
- RNAi for bone disorders
- RNAi for treatment of osteoporosis
- Research relevant to RNAi-based therapies at academic institutes
- Laboratory of RNA Molecular Biology, The Rockefeller University
- RNAi Center, La Jolla Institute for Allergy & Immunology
- Clinical trials of RNAi-based therapies
- Improving efficacy of siRNAs for clinical trials by improved delivery
- Role of RNAi in development of personalized medicine
- Future prospects of RNAi
- Challenges for the development of RNAi-based therapeutics

8. Safety, regulatory and patent issues

- Introduction
- Limitations and drawbacks of RNAi
- Adverse effects of RNAi
- Effect of siRNAs on interferon response
- Detection of interferon response
- Prevention of the interferon response in RNAi
- Overcoming the innate immune response to siRNAs
- Toxicity associated with RNAi
- Selection of siRNAs to improve specificity and efficacy
- Regulatory issues relevant to RNAi
- RNAi patents
- Companies with strong patent position
- Alnylam
- Benitec
- Intradigm
- Quark Pharmaceuticals
- Sirna Therapeutics

9. Markets for RNAi Technologies

- Introduction
- Current and future market potential for RNAi technologies
- RNAi reagents
- siRNA markets
- RNAi-based drug discovery and target validation
- RNAi-based development of therapeutics
- RNAi market potential according to therapeutic areas
- Market for viral infections
- Market for cancer
- Market for age related macular degeneration
- Unmet needs in RNAi
- Strategies for marketing RNAi
- Choosing optimal indications
- Strategies according to the trends in healthcare in the next decade
- Concluding remarks

10. Companies involved in RNAi Technologies

- Introduction
- Major players in RNAi
- Profiles of companies
- Collaborations

11. References

Tables

Table 1-1: Classification of small RNA molecules

- Table 1-2: Mechanisms of small RNAs involved in gene silencing
- Table 1-3: Historical landmarks in the evolution of RNAi
- Table 2-1: RNAi versus small molecules
- Table 2-2: Providers of software for siRNA design
- Table 2-3: Methods for the production of siRNAs
- Table 2-4: Advantages and limitations of methods of shRNA-derived siRNA knockdown
- Table 2-5: Comparison of eiRNA with siRNA
- Table 3-1: Methods for miRNA target prediction
- Table 3-2: miRNA expression in neurodegenerative diseases
- Table 3-3: Dysregulation of miRNA expression in epithelial cancers
- Table 3-4: Companies involved in miRNA diagnostics and therapeutics
- Table 4-1: Methods of delivery of oligonucleotides
- Table 4-2: Methods of delivery of siRNA
- Table 4-3: Companies developing siRNA delivery technologies
- Table 5-1: RNAi libraries
- Table 6-1: Delivery of siRNAs in vivo for target validation
- Table 6-2: Selection of siRNA versus shRNA for target validation
- Table 7-1: RNAi-based therapeutic approaches
- Table 7-2: In vivo RNAi therapeutic efficacy in animal models of human diseases
- Table 7-3: Inhibition of viral replication by RNAi
- Table 7-4: Cancer-associated genes that can be targeted by RNAi
- Table 7-5: Neurological disorders that have been studied by using RNAi
- Table 7-6: Clinical trials of RNAi-based therapeutics
- Table 9-1: RNAi markets according to technologies and reagents 2012-2022
- Table 9-2: Markets for RNAi therapy for selected diseases: years 2012-2022
- Table 10-1: RNAi reagent, technology and service companies
- Table 10-2: Pharmaceutical companies using RNAi for drug discovery and development
- Table 10-3: Biotechnology companies using RNAi for drug discovery and development
- Table 10-4: Companies developing RNAi-based therapeutic products
- Table 10-5: Major players in RNAi
- Table 10-6: Proprietary reagents of ImuThes
- Table 10-7: Product pipeline of Silence Therapeutics
- Table 10-8: Collaborations in RNAi technologies

Figures

- Figure 1-1: Relationship of DNA, RNA and protein in the cell
- Figure 1-2: Schematic of suppression of gene expression by RNAi
- Figure 2-1: Overview of ShortCut RNAi Kit
- Figure 2-2: Gene silencing by RNAi induced with ddrRNAi
- Figure 3-1: A schematic miRNA pathway
- Figure 3-2: Molecular mechanisms of miRNA generation
- Figure 4-1: RNA aptamer-mediated targeted RNAi delivery in cancer therapy
- Figure 7-1: Targeting disease by RNAi
- Figure 7-2: Role of RNAi in personalized medicine
- Figure 8-1: Problems with use of synthetic siRNAs and measures to prevent them
- Figure 9-1: Unmet needs in RNAi technologies

Ordering: Order Online - <http://www.researchandmarkets.com/reports/42874/>

Order by Fax - using the form below

Order by Post - print the order form below and send to

Research and Markets,
Guinness Centre,
Taylors Lane,
Dublin 8,
Ireland.

Fax Order Form

To place an order via fax simply print this form, fill in the information below and fax the completed form to 646-607-1907 (from USA) or +353-1-481-1716 (from Rest of World). If you have any questions please visit

<http://www.researchandmarkets.com/contact/>

Order Information

Please verify that the product information is correct and select the format(s) you require.

Product Name: RNAi - Technologies, Markets and Companies
Web Address: <http://www.researchandmarkets.com/reports/42874/>
Office Code: OC8DIROTUTNUSZ

Product Formats

Please select the product formats and quantity you require:

	Quantity	
Electronic - Single User:	<input type="checkbox"/>	€3,106
Hard Copy:	<input type="checkbox"/>	€3,417 + Euro €50 Shipping/Handling
Electronic and Hard Copy (PDF) - Single User:	<input type="checkbox"/>	€3,805 + Euro €50 Shipping/Handling
Electronic - Enterprisewide:	<input type="checkbox"/>	€9,319

* Shipping/Handling is only charged once per order.

Contact Information

Please enter all the information below in **BLOCK CAPITALS**

Title: Mr Mrs Dr Miss Ms Prof

First Name: _____ Last Name: _____

Email Address: * _____

Job Title: _____

Organisation: _____

Address: _____

City: _____

Postal / Zip Code: _____

Country: _____

Phone Number: _____

Fax Number: _____

* Please refrain from using free email accounts when ordering (e.g. Yahoo, Hotmail, AOL)



Payment Information

Please indicate the payment method you would like to use by selecting the appropriate box.

- Pay by credit card:
 - American Express
 - Diners Club
 - Master Card
 - Visa

Cardholder's Name _____

Cardholder's Signature _____

Expiry Date _____ | _____

Card Number _____

CVV Number _____

Issue Date _____ | _____

(for Diners Club only)

- Pay by check:

Please post the check, accompanied by this form, to:

Research and Markets,
Guinness Center,
Taylors Lane,
Dublin 8,
Ireland.

- Pay by wire transfer:

Please transfer funds to:

Account number	833 130 83
Sort code	98-53-30
Swift code	ULSBIE2D
IBAN number	IE78ULSB98533083313083
Bank Address	Ulster Bank, 27-35 Main Street, Blackrock, Co. Dublin, Ireland.

If you have a Marketing Code please enter it below:

Marketing Code: _____

Please note that by ordering from Research and Markets you are agreeing to our Terms and Conditions at <http://www.researchandmarkets.com/info/terms.asp>

Please fax this form to:
(646) 607-1907 or (646) 964-6609 - From USA
+353-1-481-1716 or +353-1-653-1571 - From Rest of World